Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

Limited data exist on the optimal duration of immunotherapy, including for non–small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-year fixed-duration versus continuous therapy on the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Waterhouse, David M., Garon, Edward B., Chandler, Jason, McCleod, Michael, Hussein, Maen, Jotte, Robert, Horn, Leora, Daniel, Davey B., Keogh, George, Creelan, Ben, Einhorn, Lawrence H., Baker, Justin, Kasbari, Samer, Nikolinakos, Petros, Babu, Sunil, Couture, Felix, Leighl, Natasha B., Reynolds, Craig, Blumenschein, George, Gunuganti, Vijay, Li, Ang, Aanur, Nivedita, Spigel, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676888/
https://www.ncbi.nlm.nih.gov/pubmed/32910710
http://dx.doi.org/10.1200/JCO.20.00131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676888/
https://www.ncbi.nlm.nih.gov/pubmed/32910710
http://dx.doi.org/10.1200/JCO.20.00131

Ejemplares similares